These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15835738)

  • 1. Compartmental modeling of transdermal iontophoretic transport II: in vivo model derivation and application.
    Nugroho AK; Della-Pasqua O; Danhof M; Bouwstra JA
    Pharm Res; 2005 Mar; 22(3):335-46. PubMed ID: 15835738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compartmental modeling of transdermal iontophoretic transport: I. In vitro model derivation and application.
    Nugroho AK; Della Pasqua O; Danhof M; Bouwstra JA
    Pharm Res; 2004 Nov; 21(11):1974-84. PubMed ID: 15587918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle.
    Gratieri T; Pujol-Bello E; Gelfuso GM; de Souza JG; Lopez RF; Kalia YN
    Eur J Pharm Biopharm; 2014 Feb; 86(2):219-26. PubMed ID: 23791718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient.
    Junginger HE
    Adv Drug Deliv Rev; 2002 Nov; 54 Suppl 1():S57-75. PubMed ID: 12460716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro.
    Li GL; Danhof M; Frederik PM; Bouwstra JA
    Pharm Res; 2003 Apr; 20(4):653-9. PubMed ID: 12739775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin.
    Nolan LM; Corish J; Corrigan OI; Fitzpatrick D
    Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mathematical models to describe iontophoretic transport in vitro and in vivo and the effect of current application on the skin barrier.
    Gratieri T; Kalia YN
    Adv Drug Deliv Rev; 2013 Feb; 65(2):315-29. PubMed ID: 22626977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies.
    Li GL; Grossklaus A; Danhof M; Bouwstra JA
    Int J Pharm; 2003 Nov; 266(1-2):61-8. PubMed ID: 14559394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iontophoretic delivery of apomorphine. I: In vitro optimization and validation.
    van der Geest R; Danhof M; Boddé HE
    Pharm Res; 1997 Dec; 14(12):1798-803. PubMed ID: 9453071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment.
    Li GL; de Vries JJ; van Steeg TJ; van den Bussche H; Maas HJ; Reeuwijk HJ; Danhof M; Bouwstra JA; van Laar T
    J Control Release; 2005 Jan; 101(1-3):199-208. PubMed ID: 15588905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled iontophoretic delivery of pramipexole: electrotransport kinetics in vitro and in vivo.
    Kalaria DR; Patel P; Merino V; Patravale VB; Kalia YN
    Eur J Pharm Biopharm; 2014 Sep; 88(1):56-63. PubMed ID: 24525072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration.
    Nugroho AK; Li GL; Danhof M; Bouwstra JA
    Pharm Res; 2004 May; 21(5):844-50. PubMed ID: 15180344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.
    van der Geest R; van Laar T; Gubbens-Stibbe JM; Boddé HE; Danhof M
    Pharm Res; 1997 Dec; 14(12):1804-10. PubMed ID: 9453072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lontophoretic delivery of apomorphine in vitro: physicochemic considerations.
    Li GL; Danhof M; Bouwstra JA
    Pharm Res; 2001 Nov; 18(11):1509-13. PubMed ID: 11758756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro and in-vivo transdermal iontophoretic delivery of tramadol, a centrally acting analgesic.
    Takasuga S; Yamamoto R; Mafune S; Sutoh C; Kominami K; Yoshida Y; Ito M; Kinoshita M
    J Pharm Pharmacol; 2011 Nov; 63(11):1437-45. PubMed ID: 21988424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of in-vivo iontophoretic drug release data from in-vitro experiments-insights from modeling.
    Simon L; Ospina J; Ita K
    Math Biosci; 2015 Dec; 270(Pt A):106-14. PubMed ID: 26519787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the permselective properties of rabbit skin during transdermal iontophoresis.
    Nicoli S; Cappellazzi M; Colombo P; Santi P
    J Pharm Sci; 2003 Jul; 92(7):1482-8. PubMed ID: 12820152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species.
    Kanikkannan N; Singh J; Ramarao P
    J Control Release; 2001 Mar; 71(1):99-105. PubMed ID: 11245911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal iontophoretic delivery of tacrine hydrochloride: Correlation between in vitro permeation and in vivo performance in rats.
    Patel N; Jain S; Lin S
    Int J Pharm; 2016 Nov; 513(1-2):393-403. PubMed ID: 27633278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal iontophoretic drug delivery: advances and challenges.
    Ita K
    J Drug Target; 2016; 24(5):386-91. PubMed ID: 26406291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.